USPTO grants patent for Quick-Med's proprietary NIMBUS polymeric antimicrobial technology

Quick-Med Technologies, Inc. (OTCBB:QMDT), a leader in developing innovative antimicrobial technologies for the healthcare and consumer markets, today announced that it has been granted U.S. Patent No. 7,709,694 from the United States Patent and Trademark Office (USPTO). The patent for company's proprietary NIMBUS® polymeric antimicrobial technology is applicable to a variety of base materials including woven and nonwoven fabrics. 

"This patent issuance significantly enhances the current protection for our proprietary NIMBUS technology, further validating its innovative nature," said J. Ladd Greeno, Quick-Med's CEO. "Further, the patent underscores our leadership in developing the first non-leaching antimicrobial available in a wound dressing. While other antimicrobial dressings rely on the release of chemicals into the wound bed that can impede the wound healing process, a non-leaching antimicrobial dressing represents a significant improvement."

The broad range of materials covered under the provisions of the patent include those that are composed of natural fibers, such as cotton and wool, as well as synthetics such as polyurethane, polyester, nylon and polypropylene. The applications included in the allowed claims are for a full spectrum of products such as medical devices including wound and burn dressings and blood transfer and storage products, surgical drapes and gowns, bedding, industrial and military protective wear and consumer apparel plus hygienic products such as wipes, diapers and feminine care.

Source:

Quick-Med Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aptamer extends agreement with genetic medicines customer